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Abstract
Aim-To investigate serum placental-
type alkaline phosphatase (PLAP-type)
activities in women with squamous and
glandular malignancies of the reproduc-
tive tract using an immunoradiometric
assay.
Methods-PLAP-type immunoreactivity
was measured in 180 women with non-
ovarian malignancies of the reproductive
tract and the values were compared with
those from 334 controls. The cases
comprised 18 vulval, nine vaginal, 103
cervical, 46 endometrial, and five fal-
lopian tube cancers.
Results-Serum PLAP-type activities
were no different from controls in
patients with squamous cell tumours.
Women with adenocarcinoma of the
cervix, endometrium, and fallopian tube
had increased values: women with
endometrial cancer had a median value
nearly four times greater than that of
controls. There was no direct correlation
between PLAP-type activities and stage
of disease in patients with endometrial
cancer, but values reverted to normal
after treatment.
Conclusions-Serum PLAP-type mea-
surements are ofno value in the manage-
ment of patients with squamous cell
tumours ofthe female reproductive tract.
Raised activities can, however, be found
in glandular tumours, in particular
endometrial cancer where serum PLAP-
type measurements may be of value in
predicting remission.
(7 Clin Pathol 1994;47:1035-1037)
Serum measurement of placental alkaline
phosphatase (PLAP) can be used as a tumour
marker for testicular and ovarian cancer.' 7 In
vitro studies have shown that PLAP is also
produced by non-ovarian malignancies of the
female reproductive tract.89 Several groups
have measured PLAP and PLAP-like material
in the serum of patients with non-ovarian
gynaecological cancers, but the results have
been conflicting.'0 16 A possible reason for the
divergent results was that most groups mea-
sured the intrinsic alkaline phosphatase activity
of the protein, and this may be defective in
ectopically produced PLAP.17 18 In addition,
factors such as smoking, ABO blood group,
and menopausal status may substantially
affect circulating concentrations.'8"23
We re-evaluated serum PLAP-type concen-
trations in women with non-ovarian malig-
nancies of the reproductive tract using an
assay that measures immunoreactivity rather
than enzymatic activity. Our results have been
corrected for smoking habits, menopausal sta-
tus, and ABO blood group.
Methods
One hundred and eighty patients with non-
ovarian malignancies of the female reproduc-
tive tract had blood taken before treatment.
These included patients with vulval, vaginal,
cervical, endometrial, and fallopian tube can-
cers (17, nine, 103, 46, and five, respectively).
In 14 cases of adenocarcinoma of the cervix
and endometrium squamous change was
found, and these patients were considered
separately in the results.
A further 14 samples were collected from
the same patients with endometrial cancer fol-
lowing treatment and a period of remission.
Three hundred and thirty four women with
non-pregnancy related, non-neoplastic, or
benign neoplastic gynaecological disease
served as controls. The serum PLAP-type
activities in some of the control group have
been reported before.8
Samples were received as coded specimens
and stored at - 20°C. PLAP-type immunore-
activity was measured by immunoradiometric
assay (IRMA).24 This uses the monoclonal
antibody H7 (InRo, Sweden) for capture and
H 17E2 (Unilever UK) for detection. The
IRMA has a sensitivity of 0-1 IU/l and has no
cross-reactivity with intestinal or tissue non-
specific alkaline phosphatase.
PLAP values were measured in interna-
tional units and expressed as multiples of the
regressed control group median (MoM) after
correction for smoking, ABO blood group and
menopausal status. The equation used was:
PLAP = 10'- 0-065 - (0.14 M + (0T35h S) +
(0.018> A) + (0.22X B)
where M = menopausal status (1 = pre-
menopausal, 2 = post-menopausal); S =
smoking habits (0 = non-smoker, 1 =
smoker); A = number of cigarettes smoked
per day; and B = ABO blood group (1 =
blood groups A and AB, 2 = 0 and B). A
MoM of 7X4 (100th centile for controls) was
used as a cut off. PLAP values were compared
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Table 1 Serum PLAP-type activities in women with non-ovarian malignant disease of the reproductive tract, and
statistical comparison with the control group of334 women
Per cent Median Range Mann-Whitney 95% CI in cases
positive (MoM) (MoM) U statistic p value (controls)
Uterus
Adenocarcinoma 37 (13/35) 3-6 0-2-310 9203 <0 0001 07-4 9
Adenocarcinoma with
squamous change 18 (2/11) 5-2 12-46 6 3383 <0-0001 1-8-5-0
All uterus 33 (15/46) 4-8 0-2-310 12972 <0-0001 1-29-4-56
Cervix
Squamous 3 (2/67) 1-2 0-2-13-2 14690 0-16 -0 1-0 4
Adenocarcinoma 3 (1/33) 1-6 0-2-7-8 7534 0 01 0-6-1.6
with squamous change 0 (0/3) 1.0 0-6-1-6 509 0.99 -0-4-0-6
All cervix 3 (3/103) 1 2 0-2-13-2 25595 0 01 0 0-0 4
Vagina
Squamous 0 (0/8) 0 7 0-3-1-8 945 0-12 -0 9-0 1
Adenocarcinoma 0 (0/1) 14 -4
Allvagina 0 (0/9) 0-8 0-3-1-8 1180 0 21 -0-8-0-2
Vulva
Squamous 12 (2/17) 1.1 0-4-13 5 3630 0-12 -0 1-0 7
Fallopian tube
Adenocarcinoma 40 (2/5) 6-6 2 5-50-1 1554 0-0012 1 5-947
Table 2 Serum PLAP-type concentrations in adenocarcinoma of the cervix and
endometium by stage
Median MoM Median MoMfor
for endometrial adenocarcinoma of
Stage carcinoma (n, range) the cervix (n, range)
Unstaged 1-6 (7, 0-7-195)
Stage 1 1-7 (18, 0-2-310) 1 1 (16, 0-2-6-1)
Stage 2 6-9 (6, 1 1-94-1) 1-2 (2, 0-8-1-6)
Stage3 1 3(3,08-22) 1-9(2,0-7-3-1)
Stage 4 4-6 (6, 04-37-8) 1 1 (1,-)
New recurrence 15 4 (6, 0-3-189) 3 0 (12, 02-7 8)
between cases and controls by analysis of
MoMs using the Mann-Whitney U test.
Results
Serum PLAP-type activities were raised in
patients with adenocarcinoma of the cervix,
endometrium, and fallopian tube compared
with controls (table 1). Values were no differ-
ent from those of controls in patients with
squamous cell carcinoma of the lower genital
tract (table 1). The proportion of patients
with increased PLAP-type values was highest
in women with endometrial and fallopian tube
cancers (33 and 40%, respectively) (table 1).
Only one of the 33 (3%) patients with adeno-
carcinoma of the cervix had circulating con-
centrations greater than the 100th centile for
controls, but the median concentrations were
significantly higher than those in the controls
overall.
There was no difference in circulating
PLAP-type values between the control group
and women who were in remission after treat-
ment for carcinoma of the endometrium
(median MoM = 1-5, u = 2867, p = 0-25,
95% confidence interval for cases and con-
trols = -0-2 to 0-8, respectively). In all of
these cases serum concentrations had fallen
and were below the 100th centile for controls.
No correlation with stage was shown in
patients with adenocarcinoma of the cervix or
endometrium (table 2).
Discussion
These results clearly show that serum PLAP-
type measurements are of no value in the
management of patients with squamous cell
tumours of the female reproductive tract.
Raised values can, however, be found in some
glandular tumours, in particular endometrial
carcinoma.
Ectopic production of a PLAP-type material
was first described by Fishman et al in 1968.23
They found raised values in a man with
carcinoma of the lung. Since then, PIAP
production has been found in a number of
tumours, of which ovarian and testicular
cancers have been the most extensively
investigated. 1-6 11-16 22 26 32 However, most
assays for PLAP-type material measure the
enzymatic activity rather than protein mass.
This activity may be defective in PLAP
expressed in neoplasms.
In carcinoma of the cervix previous studies
have yielded varying results. In our study
values were raised in glandular but not squa-
mous cell tumours. In the former, activities
were greater than the 100th centile for the
control group in only 3% of cases. DeBroe et al
(1988)" found raised PLAP-type activity in
7% (five of 70) of patients. This is in contrast
to Doellgast and colleagues (1984),26 who
found raised activities in 41% (28 of 69).
Other groups have reported that between 15
and 25% of patients have increased concen-
trations.' 12 1327 A possible reason for these
varied results is the use of different cut off
levels. In addition, none of these groups'
results were corrected for smoking which is
known to cause a 10-fold rise in serum PLAP-
type activities. 18-23 There is also a strong
association between smoking and the develop-
ment of cervical cancer independent of
PLAP-type activity. One study by Muensch et
al (1986)22 excluded smokers and found
raised PLAP-type activities in 20% of patients
(one of five). However, the small number of
patients and the absence of histological data
make it difficult to draw conclusions from
their results.
Only one group (DeBroe et al, 1988)" have
measured serum PLAP-type activity in
patients with carcinoma of the vulva and
vagina. In that study concentrations were not
increased in any of their eight cases. This is
similar to the present data for PIAP-type
immunoreactivity. No group has reported on
PIAP activities in carcinoma ofthe fallopian tube.
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In endometrial carcinoma we have shown
increased activities in a third (14 of 46) of
patients. This is a higher proportion than that
found in studies using enzymatic activity. In
addition, most of these groups have used a
lower cut off level. Cadeaux et al (1974)27
found raised values in 11% (five of 44) and
DeBroe et al (1988)" in 19% (10 of 54) of
patients. Two other groups reported increased
concentrations in 15% (eight of 53) and 9%
(seven of 77) of patients.' 12 This is consistent
with in vitro studies which showed immuno-
reactive but not enzymatically active PLAP
production in endometrial tissue cultures.9
Other markers, such as CA 125 are raised
in endometrial cancer. Kenemans et al
(1988)33 performed a meta-analysis of results
from 16 groups and found high CA 125 con-
centrations (>35 U/ml) in 27% (66 of 245) of
cases of endometrial cancer. However, at this
cut off level CA 125 is increased in 20% of
patients with benign or non-neoplastic ovar-
ian masses.33 In our study we used a cut off at
the 100th centile of our control group which
included patients with benign pelvic masses.
Using these stricter criteria, we suggest that
PLAP-type immunoreactivity is a better
marker for endometrial cancer than CA 125.
If PLAP-type material is to be a useful
marker in the management of endometrial
cancer, a correlation with tumour bulk and
spread would be desirable. In this respect our
results in relation to the stage of disease are
clearly disappointing. However, all 14 blood
samples from patients in remission after treat-
ment, with raised PLAP-type activities before
treatment, were normal, suggesting that this
test may be of value in determining remission.
In conclusion, measurement of serum
PIAP-type immunoreactivity is of little value
in patients with squamous cell tumours of the
female reproductive tract but may be of value
in some patients with glandular malignancies.
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